ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1238

Incident Systemic Lupus Erythematosus in Males in a Northern California County Hospital

Jorge A. Uribe1, Julia F Simard2, Laura Tarter3 and Thomas M. Bush1, 1Medicine/Rheumatology, Santa Clara Valley Medical Center, San Jose, CA, 2Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, 3Rheumatology, Stanford University Hospital, Stanford, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Lupus and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:
Little is known
about males with systemic lupus erythematosus (SLE), particularly among those
with a recent diagnosis. To better understand the
presentation and outcomes of adult males with SLE we describe the demographic,
clinical and immunological manifestations, and treatment profiles in a small
inception cohort of men with SLE at Santa Clara Valley Medical Center (SCVMC), a
574-bed medical center in Santa Clara County.

Methods: Electronic records
were searched to identify adult males diagnosed with SLE at SCVMC between January
2004 and August 2014 with at least 2 rheumatology clinic visits and documented
SLE diagnosis within one year of their initial visit.   Medical record review
of these incident cases confirmed the diagnosis using ACR classification criteria.
Additional data collected included socio-demographic variables, history of
comorbidities at diagnosis (e.g. myositis, hypertension), clinical and
immunological SLE manifestations, clinical events after diagnosis (e.g.
avascular necrosis, cerebrovascular event, pulmonary embolism) and treatment
profiles. Individuals were followed until either the end of follow-up (August
2014), death, or loss to follow-up.

Results:
Of
the 16 incident male SLE patients identified, the average age at diagnosis was
approximately 32 years and the majority of patients were Hispanic (69%). At
initial presentation the majority of patients had arthritis (81%), history of
hyperlipidemia (69%), and history of hypertension (63%). 44% had a documental serum creatinine >1.5mg/dl with
biopsy-confirmed lupus nephritis (LN) in 6 patients (2 with class 3/4 and 4
with class 5). In the first year 81% were prescribed hydroxychloroquine, 75% corticosteroids,
38% mycophenolate mofetil, and 31% cyclophosphamide. Among the 15 contributing
more at least 2 years of follow-up the use of most of these medications
increased (93% hydroxychloroquine, 80% corticosteroids, 47% mycophenolate
mofetil, and 20% (n=3) started azathioprine) and no patients remained on
cyclophosphamide (the one patient with less than 1yr follow-up was not on this).
Of the 6 men with documented cyclophosphamide treatment during follow-up, all 6
had LN plus 2 had vasculitis and 2 had myositis. Nine of 16 (56%) men had a
notable clinical or catastrophic event during follow-up (Table 1).

Conclusion: In this case series of 16 men with recently onset SLE nearly half of the patients
had elevated serum creatinine documented and 37.5% biopsy confirmed LN. This is
similar to reported LN incidence (44.8%) among a Spanish subset of male SLE
patients (Casas I, et al. ACR Abstract 2014 #2622). More than half experienced at
least one catastrophic event and over 37% of subjects required cyclophosphamide
at one point. This is one of the first studies to look at treatment of male SLE
and more information is needed both with respect to sex differences and male
SLE outcomes.

Table 1. Documented clinical outcomes and catastrophic events during follow-up among SCVMC males with incident SLE (n=16), presented as %

Myocardial infarction

0

CAD/ischemia

0

Avascular necrosis

12.5

Cerebrovascular accident/TIA

18.8

CHF

6.3

Blindness

0

APLS

12.5

History of hemodialysis

12.5

Pulmonary embolus

12.5

Death

6.3

 


Disclosure: J. A. Uribe, None; J. F. Simard, None; L. Tarter, None; T. M. Bush, None.

To cite this abstract in AMA style:

Uribe JA, Simard JF, Tarter L, Bush TM. Incident Systemic Lupus Erythematosus in Males in a Northern California County Hospital [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/incident-systemic-lupus-erythematosus-in-males-in-a-northern-california-county-hospital/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incident-systemic-lupus-erythematosus-in-males-in-a-northern-california-county-hospital/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology